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Introduction
 The annual incidence of cervical cancer worldwide 
has increased by 0.6%, from 378,000 cases in 1980 to 
454,000 cases in 2010 (Forouzanfar et al., 2011). It is 
one of the most common cancers in developing countries, 
and it also represents a major health issue in Korea and 
Japan, economically developed Asian nations (Konno et 
al., 2008; Razak et al., 2013). In Korea, cervical cancer 
accounted for 9.8% of new cancer cases in 2002, although 
the age-standardized incidence has steadily declined from 
19 per 100,000 women in 1993-1995 to 15 per 100,000 
women in 1999-2002 (Chung et al., 2006; Shin et al., 
2007).
 In Japan, the Papanicolaou (Pap) smear, the 
conventional cytological method for cervical cancer 
mass screening, is used in an organized cervical cancer 
screening program (Konno et al., 2008). In Korea, a 
National Cancer Screening Program (NCSP) including 
the Pap smear was established in 1999, and, since 2002, 
coverage has included all National Health Insurance (NHI) 
beneficiaries and Medical Aid recipients (Cho et al., 2013). 
 Several studies have reported beneficial outcomes 
associated with cervical cancer screening. For instance, in 
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Abstract
 Background: Cervical cancer, which is common in developing countries, is also a major health issue in 
Korea. Our aim was to evaluate the cost-effectiveness of Korea’s National Cancer Screening Program (NCSP), 
implemented in 1999. Materials and Methods: The target population was Korean women 30 years or over who 
were invited to take part in the NCSP in 2002–2007. By merging NCSP records with Korean Central Cancer 
Registry data, patients diagnosed with cervical cancer who had been screened were assigned to a “screened group,” 
while patients diagnosed elsewhere were assigned to a “non-screened group.” Clinical outcomes were measured 
in terms of life-years saved (LYS), derived from 5-year mortality rates supplied by the Korean National Health 
Insurance Corporation and National Statistical Office. Direct and travel costs associated with screening were 
evaluated from the perspective of the payer, the NCSP. Results: A diagnosis via screening was associated with 2.30 
LYS, and the incremental cost-effectiveness ratio (ICER) estimate for screening was 7,581,679 KW/LYS (6,727 
USD/LYS). ICER estimates were lower for older patients (≥ 50 years) than younger patients (4,047,033 KW/
LYS vs 5,680,793 KW/LYS). The proportion of early-stage cancers detected was 16.3% higher in the screened 
group. Conclusions: In light of Korea’s per capita gross domestic product (32,272 USD in 2012), the current 
NCSP’s incremental cost per LYS appears acceptable.
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one Japanese prefecture, screening participation increased 
from 0.2% in 1961 to 30.4% in 1991, and cervical-cancer 
related mortality fell from 12.1 per 100,000 in 1961 to 
4.0 per 100,000 in 1994 (Sato et al., 1998). Similarly, a 
cohort study found that Korean women who had been 
screened more than once had a significantly reduced risk 
of invasive cervical cancer or carcinoma in situ compared 
to unscreened women (Jun et al., 2009). Studies of the 
cost-effectiveness of Pap screening strategies have also 
been conducted in Asian countries. However, most of them 
have used hypothetical economic evaluation models rather 
than assessing empirical data (Koong et al., 2006; Woo et 
al., 2007; Chen et al., 2011; Zhao et al., 2012).
 The purpose of the present study was to use empirical 
data to investigate the life years saved (LYS) by cervical 
cancer diagnosis through the Korean NCSP. In addition, 
the cost of administering the NCSP was examined in terms 
of LYS. 
Materials and Methods
Study population and data sources
 The target population was Korean women 30 years or 
older who were invited to participate in cervical cancer 
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screening provided by the NCSP between 2002 and 2007. 
The NCSP’s cervical cancer screening initially included 
all Medical Aid Program recipients, and, in 2002, it 
expanded to include all NHI beneficiaries as well (Jung 
et al., 2010; Han et al., 2012). However, because of the 
separation of administrative management for NCSP, the 
NCSP database used in this study included only a subset 
of the individuals covered according to screening years. 
For the years 2002-2004, only Medical Aid Program 
recipients were included in the NCSP database records. 
All Medical Aid Program recipients and National Health 
Insurance (NHI) beneficiaries were included in the NCSP 
database in 2005-2006. Finally, in 2007, Medical Aid 
Program recipients and NHI beneficiaries in the bottom 
50% by income were included in the database. 
 The NCSP invited women to undergo cervical cancer 
screening at their even-numbed ages. Using NCSP records, 
individuals who had received cervical cancer screening 
were identified and assigned to the ‘screened group.’ 
Women who did not undergo screening were assigned to 
the ‘non-screened group’. 
 Cervical cancer diagnoses in the study population were 
identified using Korean Central Cancer Registry (KCCR) 
data. The detected cancers were classified by cervical 
intraepithelial neoplasia (CIN) stage and spread: CIN 
1/2, local (CIN 3), regional, and distant. Cervical cancer-
related mortality was determined by merging databases 
from the Korea National Health Insurance Corporation 
and the National Statistical Office. Cost data relevant to 
screening participation were obtained directly, from the 
internal accounts of screening units, and indirectly, from 
published studies and national statistics. 
Cost-effectiveness analyses
 Cost-effectiveness outcomes were examined from 
the perspective of the payer, the NCSP. The information 
used in the cost-effectiveness models is presented in 
Table 1. In the COST I model, which dealt with direct 
costs, expenditures related to screening and follow-up 
examinations were considered. Follow-up examination 
costs were included only for patients for whom the screen 
yielded a false positive, as follow-up examinations for 
true-positive cancer patients can be viewed as a part of 
the treatment course instead.
 The costs associated with traveling to attend screening 
or follow-up examinations may also be considered 
screening costs, so the COST II model consisted of the 
data included in COST I as well as these indirect costs. 
Because screening and travel costs occurred only if people 
utilized NCSP cervical cancer screening, the COST I and 
COST II models were only applied to individuals who had 
been screened. All costs were inflated to 2009 values using 
the National Consumer Indices (Statistics Korea, 2012).
 To measure the effectiveness of the national cervical 
cancer screening program, we examined 5-year survival 
rates and LYS, starting from the year of diagnosis. In 
determining LYS, people with no mortality record during 
the 5-year follow-up period were assumed to live until 
the last year of their life expectancy (Korean Statistical 
Information Service: KOSIS, 2012). 
 Individuals in both the screened and non-screened 
groups were divided into 5-year age groups according 
to their age at screening or diagnosis. Both effectiveness 
outcomes and costs were presented per 100,000 people, 
stratified by age group, to facilitate comparison of the 
screened and non-screened groups. Outcome information 
for the total sample was age-adjusted to match the age 
distribution in Korea as a whole (KOSIS, 2012). 
 To determine cost-effectiveness of NCSP cervical 
cancer screening, cost and effectiveness outcomes 
associated with cervical cancer diagnoses in the screened 
and non-screened groups were compared. The sums 
obtained in COST I and COST II were divided by the 
number of cervical cancer cases diagnosed via screening. 
Then, the incremental costs attributable to the screening 
program were evaluated based on the LYS from 2002-
2007. In addition, the incremental costs needed to detect 
additional early-stage cervical cancer cases via screening 
were examined by considering diagnoses of CIN 1/2 
or local-stage cervical cancer. Data management and 




 According to our database, the average cervical cancer 
screening participation rate in 2002-2007 was 20.2% 
(Table 2). Women 55-59 years old had the highest rate of 
participation, at roughly 30%. Women in their early 30s 
and women over 75 years of age had the lowest NCSP 
participation rates (Table 2). 
Table 1. Costs Relevant to Participation in Korea’s National Cervical Cancer Screening Program
Cost type Amount (KW) Source
Cost I Model: Direct screening costs 
 (1) Cost of screening test: Pap smear+consultation 10,880 KW National Cancer Screening Program guidebook. 2002-2011.
  (5,760+5,120) Division of Cancer Policy, Ministry of Health and Welfare
 (2) Costs of follow-up testing caused by false- 511,704 KW (b) (c): National Cancer Center Hospital, Goyang
 positive screening results: (a) Colposcopy+ (6,390+17,970+ (d) (e): Division of Medical Information and Technology,
 (b) biopsy+(c) histopathologic exam+ 19,690+16,880+ Yonsei University Health System, Seoul
 (d) consultation+(e) specialty consultation fee 50%*5,648) 
Cost II Model: Cost I+travel costs  
 Round-trip travel costs 23,404 KW  Third Korea National Health and Nutrition Examination 
  (11,702*2) Survey (KNHANES Ⅲ), 2005
*All unit costs were inflated to 2009 values; aThe cost for the specialty consultation fee was multiplied by 50% for this analysis, under the assumption that half of the 
participants with false-positive screening results received a specialty consultation and the remaining half were retested by a general physician; KW, Korean Won
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Table 2. The Proportion of Korean Women Who 
Participated in Cervical Cancer Screening in 2002–
2007
Age group (years) Screened Non-screened
   30–34 6.30% 93.80%
   35–39 10.10% 90.00%
   40–44 20.70% 79.30%
   45–49 23.70% 76.30%
   50–54 28.60% 71.40%
   55–59 30.30% 69.70%
   60–64 28.10% 71.90%
   65–69 21.30% 78.70%
   70–74 14.50% 85.50%
   75–79 7.80% 92.20%
   ≥80 2.50% 97.50%
Total 20.20% 79.80%
*The study population included (1) Medical Aid Program recipients from 
2002–2004; (2) the entire national population in 2005–2006; and (3) Medical Aid 
Program recipients and the bottom 50% of NHI beneficiaries by income in 2007. 
Total participation rate was age-adjusted
Table 4. Total Direct and Indirect Screening Costs per 
Cervical Cancer Diagnosis in the Screened Group, 
2002-2007
 Cost I (KW)/diagnosis Cost II (KW)/diagnosis
Age group (years)
 30–34 7,789,196 17,856,498
 35–39 6,661,463 15,295,865
 40–44 7,043,672 16,782,755
 45–49 7,142,240 17,111,208
 50–54 9,415,293 22,731,449
 55–59 8,447,979 20,335,036
 60–64 7,318,320 17,616,911
 65–69 7,059,043 16,947,479
 70–74 4,803,405 11,559,339
 75–79 6,179,769 14,732,680
 ≥80 7,013,513 16,561,384
Total  7,323,019 17,721,662 
*Cost I includes direct screening costs for cervical cancer. Cost II includes direct 
plus indirect (i.e. travel) costs. Total costs were age-adjusted and inflated to 2009 
values
Table 3. Number of Cervical Cancer Cases Detected 
per 100,000 Korean Women and 5-year Mortality
 Cervical cancer diagnoses 5-year mortality rate of
 per 100,000 women patients with cervical cancer
  Screened Non-screened Screened Non-screened
Screening year
 2002 145.9 67.4 5.20% 35.90%
 2003 185.6 59.6 12.60% 31.20%
 2004 168.8 52.2 11.10% 31.30%
 2005 118.2 48.5 5.90% 15.30%
 2006 111.9 48 4.40% 12.70%
 2007 102.7 49.3 2.80% 16.20%
 Total 114.5 49.5 4.90% 16.60%
*The total frequency values were age-adjusted. Cervical cancers in the screened 
Table 5. Incremental Life Years Saved (LYS) and 
Incremental Cost-Effectiveness Ratios (ICERs) for 
Cervical Cancer Screening: 2002–2007
 LYS/diagnosis ICER
  Cost I (KW)/LYS Cost II (KW)/LYS
Age group (years)
 30–34 0.2 38,694,716 88,706,474
 35–39 0.88 7,582,464 17,410,642
 40–44 1.96 3,586,190 8,544,713
 45–49 2.1 3,405,098 8,157,851
 50–54 3.14 3,000,149 7,243,295
 55–59 2.98 2,837,704 6,830,606
 60–64 2.42 3,019,387 7,268,372
 65–69 3.18 2,222,291 5,335,317
 70–74 2.86 1,681,717 4,047,033
 75–79 2.59 2,382,865 5,680,793
 ≥80 2.5 2,799,933 6,611,631
Total 2.31 3,175,535 7,581,679 
*Total LYS and ICERs were age-adjusted. The LYS outcomes were derived from the 
5-year period following diagnosis. All cost estimates were adjusted to 2009 values
 In 2002, the age-adjusted rate of cervical cancer 
diagnosis via the NCSP was 146 per 100,000 screening 
participants (Table 3). The detection rate peaked in 2003-
2004, at 186 cancers per 100,000 screenings. Then, the 
NCSP detection rate gradually decreased; by 2007, it 
had fallen to 103 cervical cancer diagnoses per 100,000 
screenings. The incidence of cervical cancer diagnoses 
among non-NCSP participants was 49.5 per 100,000 
in 2002-2007, accounting for roughly 30% of cervical 
cancers diagnosed in Korea (Table 3). Overall, the rate of 
cervical cancers diagnosed was more than twice as high 
in the screened group. During 2003 and 2004, the NCSP 
rate of cervical cancer diagnosis was more than triple that 
in the non-screened group (Table 3). 
Incremental clinical and cost outcomes
 Among cervical cancer patients screened by the NCSP 
in 2002-2007, 4.9% died within 5 years. At 16.6%, the 
5-year mortality for patients diagnosed with cervical 
cancer though a route other than the NCSP was more 
than triple that (Table 3). Although the 5-year mortality 
rate among screened cancer patients was over 10% in 
2003-2004, by 2007 it had dropped to 2.8%. Likewise, 
the mortality rates among non-screened cervical cancer 
patients in 2005 and 2006, which were 15.3% and 12.7%, 
respectively, were half those seen in the previous years 
(Table 3). Mortality in this group did increase slightly in 
2007, however, to 16.2%. 
 Based on the expenditures associated with screening 
listed in Table 1, direct and indirect costs per cervical 
cancer diagnosis were estimated using the COST I and 
COST II models (Table 4). In 2002-2007, the average 
direct cost of screening was 7,323,019 Korean Won (KW) 
(equivalent to 6,498 US Dollars, USD; exchange rate May 
2013 1 USD=1,127 KW) per cervical cancer diagnosis, 
while the average total cost was roughly two times greater 
(17,721,662 KW; 15,725 USD). 
 Based on a 5-year follow-up of all patients diagnosed 
with cervical cancer, the number of incremental LYS 
by screening was 2.31 years (Table 5). The number of 
LYS was greatest for the age groups 65-69 years (3.18 
per diagnosis) and 50-54 years (3.14 per diagnosis). By 
contrast, in women in their 30s, the incremental LYS was 
less than 1 year (Table 5). 
 Using the COST I model, the incremental cost-
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effectiveness ratio (or ICER, obtained from the ratio of 
incremental cost:LYS) was 3,175,535 KW/LYS (2,818 
USD/LYS) per cervical cancer patient (Table 5). Using the 
COST II model, the ICER was 7,581,679 KW/LYS (6,727 
USD/LYS). With regard to age, the ICER associated 
with the cervical cancer screening program was lowest 
(4,047,033-5,680,793 KW/LYS) in the 65-79 year-old age 
group and highest (17,410,642-88,706,474 KW/LYS) in 
the 30-39 year old age group (Table 5). 
 In 2002-2007, the NCSP for cervical cancer was 
associated with a 16.3% increase in early-stage detection 
relative to the non-screened group (Table 6). The 
difference in the proportion of early-stage cancers 
diagnosed was roughly 20% in patients over the age of 50. 
By contrast, among women aged 30-34 years, the increase 
in the early-stage detection rate associated with screening 
was only 4.0%. 
 For each 1% increase in the early-stage cervical cancer 
detection rate via screening, the associated direct costs 
were 418,901 KW (372 USD, Table 6). When both direct 
and indirect costs were considered, the ICER for the same 
increase was 1,000,138 KW (887 USD). The age groups 55 
years and over had ICER estimates below the age-adjusted 
average for the sample as a whole (Table 6).
Discussion
The 5-year survival rate for cervical cancer patients in 
1993-2002 was reported to be 78.7% (Jung et al., 2007). 
This estimate is significantly lower than that identified in 
our research (95.1% in the screened group; 83.4% in the 
non-screened group), which focused on patients diagnosed 
from 2002-2007. It is likely that the introduction of the 
NCSP in 1999 and the gradual expansion of beneficiaries 
have partially contributed to increased cervical cancer 
survival rates. Indeed, our results reveal a trend of 
decreasing 5-year mortality rates, with the exception of the 
baseline year 2002 (Table 3). The 5-year mortality estimate 
for cervical cancers identified in 2005-2007 was less than 
half the estimate for cancers identified in 2003-2004. 
We found that the average incremental direct screening 
cost was 3,175,535 KW/LYS (2,818 USD/LYS). When 
travel costs associated with screening were considered, 
the incremental cost doubled. From the perspective of 
the payer, the NCSP, the costs associated with adding one 
year to a cervical cancer patient’s life seem reasonable. 
In its early years, the absence of empirical data on the 
cost-effectiveness of screening was considered one of 
the NCSP’s major challenges (Kim et al., 2011). By 
demonstrating superior cost-effectiveness and survival 
outcomes, our research reveals that Korea’s NCSP for 
cervical cancer is beneficial. 
When ICER values were compared according to age 
group, women aged 30-34 years required the greatest 
incremental costs per LYS. This age group also had 
the fewest LYS (0.20) per diagnosed patient (Table 5). 
It is possible that women in their early 30s had never 
undergone cervical cancer screening before attending 
the NCSP; thus, if they did have cervical cancer, it may 
have been more likely to reach an advanced stage relative 
to the cancers detected in other age groups. In addition, 
with the exception of women aged 80 years and older, the 
participation rate in the NCSP was lowest in women aged 
30-34 years (6.3%, Table 2). This suggests that women 
in their early-to-mid 30s who underwent cervical cancer 
screening may be different from the average woman in 
this age group. Indeed, the increase in early-stage cancers 
detected via screening was lowest for the 30-34 year-old 
age group (4.0%). By contrast, ICER estimates per LYS 
were lowest for patients older than 50 years. In this age 
range, 20-35% of cervical cancers were detected at an 
early stage (Table 6), which contributed to the favorable 
ICER values. 
Recently, the prevalence of human papillomavirus 
(HPV) infection has increased in Korea, resulting in a 
continued, high burden of cervical cancer (Konno et 
al., 2008). Although two HPV vaccines are available 
in Korea, the cost of including them in the National 
Immunization program is prohibitive. Recent research 
on the implementation of wide-scale HPV vaccination 
in Asian countries has predicted beneficial clinical and 
cost-effectiveness outcomes (Ezat and Aljunid, 2010; 
Yamamoto et al., 2012). Nevertheless, from the payer’s 
perspective, the expense associated with universal HPV 
vaccination may seem overwhelming (Praditsitthikorn et 
al., 2011; Sharma et al., 2012). For this reason, continuous 
efforts to expand participation in cervical cancer screening 
are still required. Increasing the uptake of cervical 
cancer screening is especially important because even 
though the ICER of adding vaccination to the Pap smear 
screening would be an cost-effective option, women of 
low socioeconomic status are less likely to participate in 
screening or to be able to afford the vaccination (Konno 
et al., 2008; Park et al., 2011; Praditsitthikorn et al., 
2011; Yamamoto et al., 2012). The cost-effectiveness of 
vaccination in combination with frequent or infrequent 
screening by the NCSP needs to be evaluated, in light 
of young women’s low screening participation rate and 
Table 6. Incremental Detection Rate of Early-Stage 
Cancer (ESC) by Screening and Incremental Cost-
Effectiveness Ratios (ICERs) for Detection of ESCs: 
2002–2007
 Incremental ICER
 detection Cost I Cost II
 rate of ESC (KW)/LYS (KW)/LYS
Age group (years)
 30–34 4.00% 1,945,194 4,459,298
 35–39 9.90% 675,382 1,550,794
 40–44 9.20% 766,537 1,826,405
 45–49 12.40% 575,045 1,377,678
 50–54 19.40% 485,457 1,172,044
 55–59 24.10% 351,086 845,096
 60–64 20.40% 358,339 862,607
 65–69 28.20% 250,770 602,052
 70–74 33.50% 143,216 344,648
 75–79 24.50% 252,252 601,374
 ≥80 34.60% 202,889 479,093
Total 16.30% 418,901 1,000,138
*Total incremental detection rate of ESCs and ICERs were age-adjusted. ESC 
includes cervical intraepithelial neoplasias (CIN) of grade 1/2 and local stage (CIN 
3) cervical cancers. All cost estimates were adjusted to 2009 values
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increasing levels of HPV vaccination. 
Recently, the HPV-DNA screening test has attracted 
public attention, especially in developing countries, as 
a potentially more cost-effective alternative to the Pap 
smear (Levin et al., 2010; Flores et al., 2011). It may not 
be feasible for all women to receive regular Pap smears 
throughout their lives. Moreover, although the Pap smear 
is inexpensive, it is less accurate than the HPV-DNA test; 
therefore, screening at wider intervals with the highly-
sensitive HPV-DNA test may be more cost-effective than 
the current system (Gravitt et al., 2010; Levin et al., 2010; 
Chen et al., 2011; Flores et al., 2011; Shi et al., 2011). 
While HPV-DNA tests are not covered under the current 
NCSP, previous studies comparing screening methods 
have reported that the sensitivity of the Pap smear was 
improved markedly in combination with the HPV-DNA 
test (Kim et al., 2013). Further research examining the 
cost-effectiveness of single and combination test screening 
should be conducted to determine the most practical cancer 
screening strategy.
To the best of our knowledge, this is the first study to 
use empirical data to investigate differential outcomes for 
cervical cancer cases detected through Korea’s NCSP vs 
other means. However, our study has several limitations. 
First, we did not consider treatment costs. Although cost-
effectiveness analysis was conducted from the perspective 
of the NCSP, a substantial portion of the cost of cervical 
cancer treatment is paid by NHI, a resource available to 
the public. Treatment costs for cervical cancer are not 
expected to differ between the screened and non-screened 
groups, however, because patients’ access to care is 
identical in terms of NHI coverage. 
Second, we did not consider intangible costs and 
benefits, such as anxiety or discomfort associated with 
undergoing screening. In addition, we did not examine the 
utility assigned to a reduced risk of dying from cervical 
cancer via attending the screening program. Indeed, a 
Japanese study has shown that the most common reasons 
for screening refusal are inconvenience, inadequate time, 
cost, and feelings of shame associated with the procedure 
(Konno et al., 2008). Although we assume these factors 
are relatively minor, utility considerations could cause 
the cost-effectiveness of the NCSP to deviate from our 
results. Utility assessments should be reviewed thoroughly 
in future studies. 
Third, although the NCSP is open to all Koreans, 
participation may be influenced by socioeconomic 
status or education level. Several studies of Korea’s 
national gastric cancer screening program have reported 
that people with higher incomes, more education, and 
supplementary private health insurance tend to undergo 
screening at higher rates (Kim et al., 1994; Hahm et al., 
2011; Lee et al., 2011; Park et al., 2011). These results 
suggest that the superior outcomes of patients diagnosed 
with cervical cancer by the NCSP may be influenced by 
the higher socioeconomic status of screening participants. 
This potential disparity implies that cervical cancer 
screening participation deserves attention from health 
social workers. 
In conclusion, this analysis of Korea’s national 
cervical cancer screening program demonstrates that, in 
2002-2007, a higher rate of cancers was identified in the 
screened population, and the 5-year mortality was lower 
for cases that had been screened as well. The incremental 
direct costs related to screening were between 3,175,535 
KW (2,818 USD) and 7,581,679 KW (6,727 USD) per 
LYS over a 5-year observation period, and, when evaluated 
in the light of Korea’s per capita gross domestic product 
(32,272 USD in 2012), these estimates appear very cost-
effective.
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